Antibody Combination Targets Multiple Pathways in mCRC
Major Finding: The objective response rate was 21% with panitumumab alone, 22% with panitumumab plus ganitumab, and 31% with panitumumab plus rilotumumab.
Data Source: A randomized, phase II trial among 142 patients with wild-type KRAS metastatic colorectal cancer.
Disclosures: Amgen sponsored the trial. Dr. Van Cutsem reported receiving research funding from Amgen. Dr. Bendell reported having no relevant conflicts.
"We do await further progression-free survival data, but the early look looks quite interesting," concluded Dr. Bendell. "Also, we are very interested in the biomarker data that will be associated with this looking at whether or not – like we see in non–small cell lung cancer – if over–Met expression has some sort of effect on how patients do with colorectal cancer."
Amgen sponsored the trial. Dr. Van Cutsem reported receiving research funding from Amgen. Dr. Bendell reported having no relevant conflicts of interest.
